Anti-Phospholipid IgG Test at Ayzal Lab

Anti-Phospholipid (IgG) at Ayzal Lab

The Anti-Phospholipid (IgG) antibody test is a highly specialized immunological laboratory investigation designed to detect the presence of IgG autoantibodies directed against phospholipids and phospholipid-binding proteins in the blood. Phospholipids are essential lipid components of cell membranes, playing a critical role in maintaining cellular integrity and regulating the coagulation cascade. When the immune system inappropriately produces IgG antibodies against these structures, it can lead to an increased risk of blood clot formation (thrombosis) in both arteries and veins, as well as recurrent pregnancy complications. This autoimmune state is clinically recognized as Antiphospholipid Syndrome (APS) or Hughes Syndrome.

At Ayzal Lab, located in Lahore, Pakistan, this test is performed using advanced enzyme-linked immunosorbent assay (ELISA) or chemiluminescent immunoassay (CLIA) technologies. These methodologies provide highly sensitive and quantitative measurements of IgG anti-phospholipid antibodies, ensuring clinical accuracy for patients and referring physicians. The test is of paramount importance in evaluating patients with unexplained thrombotic events, recurrent miscarriages, or those suspected of having systemic autoimmune diseases such as Systemic Lupus Erythematosus (SLE). By identifying these specific autoantibodies, clinicians can formulate targeted therapeutic strategies, including anticoagulation or antiplatelet therapy, to mitigate the risk of life-threatening thromboembolic events.

Clinical Procedure: What to Expect

Patient Preparation

Preparing for the Anti-Phospholipid (IgG) test at Ayzal Lab is straightforward, as it is a standard venipuncture procedure. Patients should observe the following guidelines to ensure an optimal testing process:

• Fasting Requirements: Routine fasting is generally not required for this test. Patients can eat and drink normally unless instructed otherwise by their physician or if other concurrent blood tests require fasting.
• Medication Review: It is critical to inform the laboratory staff and your referring physician about all medications you are currently taking, particularly anticoagulants (such as warfarin, heparin, or direct oral anticoagulants) and antiplatelet drugs, as these do not affect the antibody level itself but are vital for overall clinical interpretation.
• Hydration: Staying well-hydrated by drinking plenty of water before the test is highly recommended, as it makes the veins more accessible and facilitates a smoother blood draw.
• Stress Reduction: Minimal physical and emotional stress prior to the blood draw helps maintain stable physiological parameters.

During the Procedure

The blood collection process at Ayzal Lab is conducted by highly trained phlebotomists adhering to strict international biosafety and quality standards. The procedure involves the following steps:

• Patient Identification and Verification: The phlebotomist will verify your identity, confirm the test requested, and explain the steps of the venipuncture.
• Positioning: You will be seated comfortably in a blood collection chair, and your arm will be positioned on a supportive armrest.
• Site Selection and Sanitization: The phlebotomist will locate a suitable vein, typically in the antecubital fossa (the crook of the elbow). The skin over the selected vein is thoroughly sanitized using an antiseptic swab to prevent contamination.
• Venipuncture: A sterile, single-use needle is gently inserted into the vein. A small volume of blood is drawn into a vacuum collection tube containing a clot activator and gel for serum separation.
• Needle Removal and Hemostasis: Once the sample is collected, the needle is carefully removed, and immediate pressure is applied to the puncture site with a sterile cotton ball or gauze to stop any bleeding. A bandage is then applied.
• Duration and Experience: The entire venipuncture process takes less than five minutes. Patients may feel a mild, brief pinch as the needle enters the skin, but the procedure is generally painless.

When is an Anti-Phospholipid (IgG) Test Performed?

Evaluation of Unexplained Venous Thrombosis

Physicians frequently request the Anti-Phospholipid (IgG) test when a patient presents with unexplained blood clots in the veins, most commonly presenting as Deep Vein Thrombosis (DVT) in the lower extremities or Pulmonary Embolism (PE) in the lungs. When these clots occur without obvious risk factors—such as prolonged immobility, major surgery, or active malignancy—an underlying autoimmune hypercoagulable state like Antiphospholipid Syndrome must be investigated to guide long-term anticoagulation management.

Investigation of Arterial Thrombotic Events

Arterial thrombosis can lead to devastating clinical consequences, including ischemic strokes, transient ischemic attacks (TIAs), or myocardial infarctions (heart attacks), particularly in young individuals under the age of 50 who lack traditional cardiovascular risk factors. The presence of IgG anti-phospholipid antibodies is a strong risk factor for these arterial events, and identifying them helps specialists implement secondary prevention strategies to prevent recurrent strokes or arterial occlusions.

Recurrent Pregnancy Loss and Obstetric Complications

In obstetrics, the Anti-Phospholipid (IgG) test is a cornerstone investigation for women who have experienced recurrent, unexplained pregnancy losses (typically three or more consecutive early miscarriages before the 10th week of gestation), one or more unexplained fetal deaths after the 10th week, or premature births before the 34th week due to severe preeclampsia, eclampsia, or placental insufficiency. Detecting these antibodies allows obstetricians to initiate therapies like low-dose aspirin and low-molecular-weight heparin to improve pregnancy outcomes.

Screening in Systemic Autoimmune Diseases

Patients diagnosed with systemic autoimmune disorders, most notably Systemic Lupus Erythematosus (SLE), have a significantly higher prevalence of secondary Antiphospholipid Syndrome. Rheumatologists routinely order this test to assess the patient’s risk profile for thrombotic complications, as the co-existence of lupus and anti-phospholipid antibodies drastically alters the therapeutic approach and long-term prognosis.

Unexplained Thrombocytopenia or Prolonged APTT

An unexplained decrease in blood platelets (thrombocytopenia) or an isolated, unexplained prolongation of the Activated Partial Thromboplastin Time (APTT)—a routine coagulation screening test—can paradoxically indicate the presence of anti-phospholipid antibodies. Despite prolonging clotting times in laboratory assays, these antibodies promote clotting in vivo. This test helps resolve such diagnostic anomalies.

What Does an Anti-Phospholipid (IgG) Test Detect?

The Anti-Phospholipid (IgG) test specifically measures and detects the following clinical and immunological parameters:

• Elevated levels of IgG autoantibodies directed against negatively charged phospholipids.
• Antibodies targeting cardiolipin (anti-cardiolipin IgG), a key mitochondrial phospholipid.
• Antibodies directed against beta-2-glycoprotein I (anti-β2GPI IgG), a primary cofactor involved in antibody binding.
• The immunological basis of an acquired hypercoagulable state (thrombophilia).
• Risk stratification for recurrent venous thromboembolism (VVT).
• Risk assessment for early-onset arterial vascular disease and stroke.
• Autoimmune activity associated with active Systemic Lupus Erythematosus (SLE).
• The underlying cause of recurrent first-trimester spontaneous abortions.
• The etiology of late-term unexplained fetal demise.
• Placental vasculopathy and insufficiency leading to intrauterine growth restriction (IUGR).
• Immunological factors contributing to autoimmune thrombocytopenia.
• The presence of transient antibodies post-infection (distinguished by repeat testing).
• Persistent autoantibody positivity (confirmed by testing 12 weeks apart).
• The immunological profile of primary Antiphospholipid Syndrome (APS).
• The immunological profile of secondary Antiphospholipid Syndrome.
• Potential cross-reactivity in syphilis screening tests (false-positive VDRL/RPR).
• Antibody titers that help monitor the intensity of autoimmune responses.
• Prognostic markers for patients undergoing vascular graft surgeries.
• The necessity for long-term prophylactic antithrombotic therapy.
• The underlying cause of livedo reticularis, a mottled purplish skin discoloration associated with microvascular thrombosis.

Turnaround Time and Report Access at Ayzal Lab

At Ayzal Lab, we understand that timely diagnostic results are crucial for effective clinical decision-making and patient peace of mind. The Anti-Phospholipid (IgG) test involves sophisticated immunological analysis, and results are typically processed and verified within 24 to 48 hours of sample collection. Once the clinical pathologists verify the findings, patients receive an automated SMS notification. Reports can be easily accessed and downloaded online via the official Ayzal Lab patient portal or collected in person from our main diagnostic center in Lahore.

Anti-Phospholipid (IgG) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Anti-Phospholipid IgG Antibody Titer	Negative (< 10 GPL units/mL)	Positive (≥ 10 GPL units/mL), indicating low, medium, or high titers of autoantibodies.
Anti-Cardiolipin IgG Antibodies	Negative	Elevated levels, strongly associated with venous and arterial thrombosis.
Anti-β2-Glycoprotein I IgG	Negative	Positive, indicating high specificity for clinical Antiphospholipid Syndrome (APS).
Coagulation Correlation (APTT)	Normal range (typically 25-35 seconds)	Paradoxically prolonged APTT that does not correct with normal plasma mixing studies.
Platelet Count Correlation	Normal (150,000 – 450,000/µL)	Thrombocytopenia (low platelet count), frequently co-existing with positive IgG antibodies.
Clinical Vascular Status	No evidence of thrombosis	Presence of deep vein thrombosis, pulmonary embolism, stroke, or peripheral arterial occlusion.
Obstetric History Correlation	Normal, uncomplicated pregnancies	Recurrent early pregnancy losses, late-term fetal loss, or severe early-onset preeclampsia.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Ayzal Lab for Anti-Phospholipid (IgG)?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified pathologists and technologists specializing in immunology and autoimmune diagnostics.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the testing process.
• Quality Diagnostic Services: Ayzal Lab adheres to stringent internal and external quality control protocols to ensure maximum accuracy.
• Professional Reporting: Our reports are comprehensive, easy to understand, and structured to assist clinicians in rapid diagnosis.
• Modern Diagnostic Approach: We utilize advanced ELISA and automated immunoassay platforms for precise antibody quantification.
• Comfortable Environment: Our Lahore diagnostic center offers a clean, hygienic, and welcoming environment for all patients.
• Convenient Location: Easily accessible location in Lahore with ample parking and streamlined patient reception.
• Commitment to Accurate Diagnosis: We are dedicated to providing reliable diagnostic insights that form the foundation of effective medical treatment.